External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

Equity Bottom-Up

<ul><li>Extensive product pipelines to cover consumers’ diverse demands.</li><li>Cutia is one of the few players in the broader dermatology treatment and care market in China equipped with fully integrated capabilities.</li><li>The Company distinguished itself from peers in the industry which mostly specialize in certain fields, focusing on developing either dermatology care products or medications for treatment of certain types of diseases. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Extensive product pipelines to cover consumers’ diverse demands.Cutia is one of the few players in the broader dermatology treatment and care market in China equipped with fully integrated capabilities.The Company distinguished itself from peers in the industry which mostly specialize in certain fields, focusing on developing either dermatology care products or medications for treatment of certain types of diseases. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Cutia Therapeutics (2487 HK) – Well-positioned to capture broader dermatology market potential

China

Established in 2019 with headquarters in Shanghai, Cutia is an R&D based company mainly focusing on dermatology and aesthetics.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00